Martin Drost, MD
Internal Medicine · Miami Beach, FLNPI 1235135351
Payments from drug & device makers
Across 274 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$805
- AstraZeneca$688
- Pfizer$496
- Bayer$431
- Lilly USA, LLC$424
- Phathom Pharmaceuticals, Inc.$286
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,81698%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $805 |
| AstraZeneca | 39 | $688 |
| Pfizer | 21 | $496 |
| Bayer | 10 | $431 |
| Lilly USA, LLC | 19 | $424 |
| Phathom Pharmaceuticals, Inc. | 10 | $286 |
| AbbVie(2 entities) | 16 | $286 |
| Johnson & Johnson | 15 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $225 |
| Idorsia Pharmaceuticals US Inc | 7 | $219 |
| Amgen | 11 | $185 |
| Viiv Healthcare Company | 8 | $182 |
| Astellas Pharma US Inc | 5 | $152 |
| Exact Sciences | 8 | $149 |
| GSK | 6 | $123 |
| Abbott | 6 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $117 |
| Merck | 6 | $94 |
| Aimmune Therapeutics, Inc. | 4 | $82 |
| Sanofi Pasteur Inc. | 4 | $72 |
| Novartis | 4 | $70 |
| Amarin Pharma, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Eisai Inc. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Celltrion USA Inc. | 2 | $36 |
| IBSA Pharma Inc. | 2 | $35 |
| Ardelyx, Inc. | 2 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Gilead | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,911 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $102,873 |
| JardianceEmpagliflozin | 46 | $75,160 |
| RybelsusSemaglutide | 28 | $48,037 |
| JanuviaSitagliptin Phosphate | 26 | $36,615 |
| EliquisApixaban | 24 | $32,571 |
| MounjaroTirzepatide | 25 | $32,441 |
| FarxigaDapagliflozin Propanediol | 17 | $24,543 |
| XareltoRivaroxaban | 15 | $22,191 |
| TrulicityDulaglutide | 15 | $20,275 |
| WegovySemaglutide | 14 | $18,267 |
| LinzessLinaclotide | 19 | $16,991 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $12,989 |
| SynthroidLevothyroxine Sodium | 49 | $4,710 |
| Rosuvastatin Calcium | 335 | $4,129 |
| Atorvastatin Calcium | 458 | $4,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $805 | $169,176122 claims |
| Lilly USA, LLCMounjaro, Trulicity | $424 | $52,71540 claims |
| MerckJanuvia | $94 | $36,61526 claims |
| PfizerEliquis | $496 | $32,57124 claims |
| AstraZenecaFarxiga | $688 | $24,54317 claims |
| Johnson & JohnsonXarelto | $232 | $22,19115 claims |
| AbbVieLinzess, Synthroid | $286 | $21,70168 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,163248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Beach
- Gene NeytmanMiami Beach$4.4M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.